Town & Country Bank & Trust CO dba First Bankers Trust CO Has $4.49 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Town & Country Bank & Trust CO dba First Bankers Trust CO increased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,315 shares of the company’s stock after buying an additional 136 shares during the period. Johnson & Johnson accounts for about 2.4% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s investment portfolio, making the stock its 8th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Johnson & Johnson were worth $4,494,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $26,000. RE Dickinson Investment Advisors LLC increased its stake in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC increased its stake in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares in the last quarter. Professional Financial Advisors LLC increased its stake in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares in the last quarter. Finally, Joseph P. Lucia & Associates LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $38,000. 68.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research report on Monday, September 12th. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Citigroup reduced their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $189.78.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $163.28 on Thursday. The stock has a market cap of $429.29 billion, a P/E ratio of 23.77, a P/E/G ratio of 2.97 and a beta of 0.61. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The company has a fifty day moving average price of $168.25 and a two-hundred day moving average price of $174.16. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.48 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.7 EPS for the current year.

Johnson & Johnson announced that its board has initiated a share repurchase program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.